Searchable abstracts of presentations at key conferences in endocrinology

ea0026oc2.5 | Neuroendocrinology | ECE2011

Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinemia

Trifiro G , Mokhles M , Dieleman J , van Soest E , Mazzaglia G , Herings R , de Luise C , Ross D , Brusselle G , Colao A , Haverkamp W , Schade R , van Camp G , Zanettini R , Sturkenboom M

Background: There is growing evidence that ergot dopamine agonists (DA) may induce cardiac valve regurgitation (CVR) in persons with Parkinson’s disease (PD). It is unclear whether the CVR risk is increased with ergot-DA use in persons with hyperprolactinemia, in whom the dose is much lower.Objective: To assess the association between ergot and non-ergot DAs and CVR in patients with hyperprolactinemia and PD.Methods: Nested ca...